We consider that the ideal approach to obtain more information about GH/PRL tumors would be carrying out multicentric studies that follow the latest WHO classification recommendations for tumor classification, combining molecular and clinical information to determine the outcomes of these patients. The gene discussed is GH1; the disease is neoplasm.